Secondary virological analysis of a phase 3 RCT in clade II mpox: tecovirimat did not reduce day-8 skin culture positivity vs placebo (9% vs 12%). Treatment-emergent resistance was rare (2% randomised; 6·5% open-label), mainly in advanced HIV, with slower recovery.
RCT
Vyshenska et al. Tecovirimat treatment of clade II mpox: a virological analysis of a randomised, double-blind, phase 3 trial